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Abstract
Background: Approximately 10% of Lynch syndrome families have a mutation in MSH6 and fewer families have a
mutation in PMS2. It is assumed that the cancer incidence is the same in families with mutations in MSH6 as in
families with mutations in MLH1/MSH2 but that the disease tends to occur later in life, little is known about families
with PMS2 mutations. This study reports on our findings on mutation type, cancer risk and age of diagnosis in
MSH6 and PMS2 families.
Methods: A total of 78 participants (from 29 families) with a mutation in MSH6 and 7 participants (from 6 families)
with a mutation in PMS2 were included in the current study. A database of de-identified patient information was
analysed to extract all relevant information such as mutation type, cancer incidence, age of diagnosis and cancer
type in this Lynch syndrome cohort. Cumulative lifetime risk was calculated utilising Kaplan-Meier survival analysis.
Results: MSH6 and PMS2 mutations represent 10.3% and 1.9%, respectively, of the pathogenic mutations in our
Australian Lynch syndrome families. We identified 26 different MSH6 and 4 different PMS2 mutations in the 35
families studied. We report 15 novel MSH6 and 1 novel PMS2 mutations. The estimated cumulative risk of CRC at
age 70 years was 61% (similar in males and females) and 65% for endometrial cancer in MSH6 mutation carriers.
The risk of developing CRC is different between males and females at age 50 years, which is 34% for males and
21% for females.
Conclusion: Novel MSH6 and PMS2 mutations are being reported and submitted to the current databases for
identified Lynch syndrome mutations. Our data provides additional information to add to the genotype-phenotype
spectrum for both MSH6 and PMS2 mutations.
Introduction
Hereditary nonpolyposis colorectal cancer (HNPCC)/
Lynch syndrome (MIM 120435) accounts for approxi-
mately 2 percent of all diagnosed colorectal cancers
(CRC) [1]. Lynch syndrome is an autosomal dominantly
inherited cancer syndrome characterised by early onset
epithelial cancers. Patients with Lynch syndrome have
an increased risk of developing malignancies during
their lifetime, at a mean age of disease onset that is sig-
nificantly lower than that observed in the general popu-
lation. In addition to the high risk of developing CRC,
Lynch syndrome patients are also at risk of developing
malignancies in a variety of organs that include the
uterus, small bowel, stomach, ovary, bladder, pancreas
and the urinary tract [2,3]. A breakdown in the fidelity
of DNA mismatch repair has been shown to be the
basis of the disease. At present four genes encoding pro-
teins that are integrally involved in DNA mismatch
repair (MMR) have been clearly associated with Lynch
syndrome and these are MLH1 (MIM 120436), MSH2
(MIM 609309), MSH6 (MIM 600678) and PMS2 (MIM
600259) [4-7]. MMR provides several genetic stabilisa-
tion functions; it corrects DNA biosynthesis errors,
ensures the fidelity of genetic recombination and partici-
pates in the earliest steps of cell cycle checkpoint/con-
trol and apoptotic responses [8]. MMR gene defects
increase the risk of malignant transformation of cells, * Correspondence: Bente.Talseth-Palmer@newcastle.edu.au
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eral genes associated with epithelial integrity [8,9].
Genetic testing of MLH1 and MSH2 for Lynch Syn-
drome has been available for over a decade and during
this time significant advances in the technologies used
for diagnosis have occurred. Together with improve-
ments in technology the ability to rapidly screen addi-
tional genes associated with Lynch syndrome, MSH6
and PMS2, has become available. The MMR genes
MSH6 and PMS2 have been shown to interact with
MSH2 and MLH1, respectively [9,10]. Impediments to
screening these two genes for mutations have been the
high cost of testing and the presence of pseudogenes in
PMS2 [11-13]. Notwithstanding, some information is
available with respect to the frequency of MSH6 and
PMS2 mutations but there is relatively limited informa-
tion available regarding the spectrum of disease, espe-
cially in Australian Lynch syndrome families harbouring
deleterious changes in one of these two genes.
Approximately 10 percent of Lynch syndrome families
have a mutation in MSH6 and fewer families have a
mutation in PMS2 [14]. It is assumed that the cancer
incidence is the same in families with mutations in
MSH6 as in families with mutations in MLH1 and
MSH2 but that disease tends to occur later in life as a
result of the partial compensation provided by MSH3 in
MMR [15]. PMS2 mutations lead to an attenuated phe-
notype with weaker family history and older ages of dis-
ease onset [15]. Phenotype information for MSH6 and
PMS2 mutation carriers is therefore of great interest for
the recognition of Lynch syndrome and the formulation
of sufficient surveillance schemes.
I nt h ec u r r e n ts t u d yw er e p o r to no u rf i n d i n g so n
mutation type, cancer risk and age of diagnosis in 29
families (78 participants) with a mutation in MSH6 and
6 families (7 participants) with a mutation in PMS2.
Materials and methods
All the participants selected for this study had pre-
viously been diagnosed with Lynch syndrome and har-
boured a mutation in either MSH6 or PMS2. The study
was conducted in accordance with the Declaration of
Helsinki. Approval for the study was obtained from
Hunter New England Human Research Ethics Commit-
tee and the University of Newcastle Human Research
Ethics Committee. Written, informed consent was
obtained from all participants.
Since 1997, samples have been tested for Lynch syn-
drome/HNPCC at the Division of Genetics, Hunter
Area Pathology Service in Newcastle, New South
Wales, Australia. Information from all the samples col-
lected between 1997 and 2008 has been placed into a
database. The families were referred for genetic testing
due to a clinical diagnosis of HNPCC according to the
Amsterdam II criteria/Bethesda criteria or due to the
tumour displaying microsatellite instability (MSI) or
immunohistochemistry (IHC) demonstrating loss of
MSH6/PMS2 expression.
A total of 78 participants (from 29 Caucasian families)
with a mutation in MSH6 and 7 participants (from 6
Caucasian families) with a mutation in PMS2 were
included in the current study. A database of de-identi-
fied patient information was analysed to extract all rele-
vant information such as mutation type, cancer risk, age
of diagnosis and cancer type in this patient cohort. Of
the 29 MSH6 mutation positive families, 16 fulfilled the
Amsterdam II criteria and 1 fulfilled the Bethesda cri-
teria, while 6 did not fulfil the guidelines for either
(5 cases had loss of staining of MSH6, while 1 was MSI-
High) and in 5 families the status was unknown (no
pedigree/uninformative pedigree). Of the 6 PMS2 muta-
tion positive families, 4 fulfilled the Amsterdam II cri-
teria, while 2 families did not due to lack of family
history of cancer or uninformative pedigree.
The diagnosis of the cancers in the mutation positive
participants was confirmed in histopathological reports,
while information of cancers in family members with
unknown mutation status is collected from the family
pedigrees.
Cumulative lifetime risk for MSH6 mutation carriers
was calculated using Kaplan Meier survival analysis, and
w a sd e t e r m i n e do nt h eb a s i so fC R Cb e i n gt h e1
st pri-
mary tumour against cancer free individuals and endo-
metrial cancer being the 1
st primary tumour against
cancer free females. The observation time for the differ-
ent cases was from birth until first cancer diagnosis or
last follow-up appointment.
Results
MSH6 families
We identified 26 different MSH6 mutations in the 29
probands; a list of the mutations is shown in Table 1.
Eleven of the identified MSH6 mutations have been
reported before [16-23] and fifteen MSH6 mutations are
novel mutations (six of these have been posted on the
LOVD database and the remaining nine will be sub-
mitted). All mutations are considered causative and pre-
dictive testing has been offered to family members.
Table 1 also lists available immunohistochemistry (IHC)
and microsatellite instability (MSI) results from the par-
ticipant’s tumours. IHC results were available in 20 of
the 29 families; the tumour of 16 probands showed lack
of staining (-ve) for MSH6,2t u m o u r sw e r e- v eMSH2
but positive (+ve) for MSH6, 1 tumour showed isolated
loss of MSH6 while 1 was uninformative for MSH6 but
+ve for MLH1, MSH2 and PMS2.M S Ir e s u l t sw e r e
available from 6 probands, all displaying MSI-High
(unstable), 4 of them belonging to the -ve MSH6 group.
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Page 2 of 10Table 1 List of the MSH6 probands, IHC/MSI results and mutation information including; exon, nucleotide change,
consequence of mutation and references.
Family ID IHC/MSI results Exon Nucleotide Change Consequence of
Mutation
LOVD database ID
MSH6_10 -veMSH2, +veMSH6 1 c.1_457del Deletion DB-ID:
MSH6_00001
MSH6_8 Not available 2 c.458_627del Truncating DB-ID:
MSH6_00336
MSH6_5 -ve MSH6 3 c.458_657del Exon deletion Not previously
reported
MSH6_29 Not available 3 c.620del Frameshift Not previously
reported
MSH6_7 +ve MLH1, MSH2, PMS2. MSH6; uninformative
MSI-High
4 c.674insTG Frameshift/Stop Not previously
reported
MSH6_19 -ve MSH6 4 c.710delG Frameshift/Stop DB-ID:
MSH6_00702*
MSH6_17 Not available 4 c.723dupT Nonsense substitution/
Stop
Not previously
reported
MSH6_23 -ve MSH6 4 c.1404_1405delTC Truncating Not previously
reported
MSH6_4 -ve MSH6 MSI-High 4 c.2150_ 2153delTCAG Frameshift DB-ID:
MSH6_00175
MSH6_27 MSH6; isolated loss 4 c.2348_2349del Truncating DB-ID:
MSH6_00442
MSH6_6 Not available 4 c.2765delG Frameshift DB-ID:
MSH6_00703*
MSH6_1 Not available 4 c.2535dupT Frameshift/Stop DB-ID:
MSH6_00701*
MSH6_20 -ve MSH6 MSI-High 4 c.2731C>T Truncating DB-ID:
MSH6_00071
MSH6_16 -ve MSH6 4 c.2976delA Truncating Not previously
reported
MSH6_25 -ve MSH6 MSI-High 4 c.3142C>T Nonsense substitution Not previously
reported
MSH6_3 -ve MSH6 4 c.3172+1G>T Splice site DB-ID:
MSH6_00705*
MSH6_14 Not available 5 c.3173_3556del Deletion DB-ID:
MSH6_00482
MSH6_13
MSH6_22
-ve MSH6 -ve MSH6 5 c.3202C>T Truncating DB-ID:
MSH6_00487
MSH6_18 -ve MSH6 5 c.3261dupC Frameshift DB-ID:
MSH6_00201
MSH6_12 Not available 5 c.3261delC Frameshift/Stop DB-ID:
MSH6_00203
MSH6_9 -ve MSH6 MSI-High
MSH6_11 -ve MSH2, +ve MSH6 5 c.3268_3274delGACCTTA Truncating DB-ID:
MSH6_00706*
MSH6_21
MSH6_26
-ve MSH6 -ve MSH6 5 c.3312delT Truncating DB-ID:
MSH6_00497
MSH6_15 -ve MSH6 6 c.3439-1G>T Splice site DB-ID:
MSH6_00713*
MSH6_28 -ve MSH6 6 c.3556+3_3556
+13delGAGTTTTTTGT
Splice site DB-ID:
MSH6_00661
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Page 3 of 10Of the total 78 MSH6 mutation positive participants
belonging to 29 families, only 21 participants (27%) had
developed colorectal cancer (CRC). The average and
median age of diagnosis of CRC was 48 years, ranging
from 21 to 72 years. The median age of individuals who
were cancer free at the time of sample collection was 44
years, ranging from 18-76, and the average age of this
group was 45 years.
Cancer incidence in the MSH6 mutation positive
families includes, in order of frequency (in how many
families the cancer was observed): CRC in 23 families
(79%); cancer of the endometrium in 17 families (59%);
breast or prostate cancer in 7 families (24%); and ovar-
ian cancer in 5 families (17%). Other extra colonic can-
cers, including lung, bladder, stomach, cervical, Hodgkin
lymphoma, Non-Hodgkin lymphoma, pancreas, liver,
throat, lymphoma, thyroid, leukaemia, kidney, gallblad-
der, brain, melanoma, acute lymphoblastic leukaemia
and pituitary tumour can be seen in four or less
families. In six families, cancer of an unknown site was
recorded (Table 2). Extra colonic cancers were diag-
nosed in 2 individuals (9.5%) who had developed CRC
and in 14 individuals (25%) who had not developed
CRC. Table 3 provides detailed information about the
extracolonic cancers in these patients. A wide spectrum
of malignancies was present in the 29 MSH6 families
and individuals with two primary tumours were
observed in 14 of the 29 families (48%), see Table 2 for
details.
Lifetime/cumulative risk of developing colorectal and
endometrial cancer are shown in Figure 1 and 2 respec-
tively. The cumulative risk of CRC in both male and
female mutation carriers at 70 years of age was 61.5%
for MSH6 mutation carriers (Figure 1A), which is simi-
lar if divided by gender (Figure 1B). A difference can be
seen between males and females at an earlier age with
females only being at 21% risk at age 50 years, while
males have a risk of ~34% at 50 years of age. The cumu-
lative risk of endometrial cancer in woman at age 70
years was 65%.
Of the 53 female participants in this study, 10 had
developed endometrial cancer and the average and
median age of diagnosis was 59 and 57 years respec-
tively, ranging from 50-74 years. In 6 of the 17 families
where endometrial cancer had been recorded, there
were one or more individuals who had both endometrial
plus another primary tumour.
In 4 families pedigree information was not accessible
and in 3 families the proband was cancer free (the pro-
band is the first person tested from the family in our
laboratory, the index person of the family might have
been tested in another laboratory either national or
international). For the 22 families where full family his-
tory was available, cancer was present in one of the pro-
bands’ parents in 13 families.
PMS2 families
A list of the 4 identified PMS2 mutations can be seen in
Table 4. Three of the identified PMS2 mutations have
been reported before [24-26] and one PMS2 mutation is
a novel mutation. All mutations are considered causative
and predictive testing has been offered to family mem-
bers. Table 4 also lists the type of cancer and age of
diagnosis in the probands of these families.
The 7 PMS2 participants include 6 probands and 1
family member. Five probands had been diagnosed with
CRC at age 38, 41, 47, 55 and 60 years, one of them
(CRC at 55 years) was also diagnosed with renal cancer
at age 50 years. One proband has not developed CRC
but was diagnosed with cancer of the small intestine at
63 years of age; the family member of this proband is
currently cancer free at age 39 years.
Cancer incidence in the PMS2 mutation positive
families includes, in order of frequency (in how many
families the cancer can be seen): CRC (6 families); lung,
stomach and brain cancer (2 families); endometrial +
breast cancer, and ovarian + breast cancer (1 family);
breast, cervical, Merkel cell and small intestine cancer
(1 family).
Discussion
The MSH6 participants included in this study are repre-
sentative of all the HNPCC patients tested in New
South Wales, Australia from 1997 to 2008, which we
Table 1: List of the MSH6 probands, IHC/MSI results and mutation information including; exon, nucleotide change,
consequence of mutation and references. (Continued)
MSH6_24 Not available 7 c.3646+2dupT Splice site Not previously
reported
MSH6_2 MSI-High 8 c.3724del13 Frameshift/Stop Not previously
reported
26 different MSH6 mutations have been detected in our patient cohort. Not previously reported = not reported in the Leiden Open Variation Database (LOVD),
the Mismatch Repair Genes Variant Database (Memorial University of Newfoundland) or the InSIGHT database as a HNPCC/Lynch syndrome mutation.
DB-ID = Database identification number from LOVD.
#-ve = loss of protein expression, +ve = protein expression present.
*Submitted to LOVD by our research group.
Talseth-Palmer et al. Hereditary Cancer in Clinical Practice 2010, 8:5
http://www.hccpjournal.com/content/8/1/5
Page 4 of 10Table 2 Mutation positive family members, type of cancer, age and gender, as well as other family cancers present in
family members with unknown mutation status (all information collected from pedigrees) and whether the family
fulfilled the Amsterdam II criteria.
Mutation positive family members:
Family number - Cancer history (Age of
diagnosis or age at last follow up)
Gender Other family cancers (Age and relationship to proband) - mutation status
unknown
Fulfilled
Am II
criteria
MSH6_1- CRC (31)
MSH6_1.1- no cancer (69)
MSH6_1.2- no cancer (33)
F
F
M
1 Endometrial (63-mother), 1 CRC + Oesophagus (mothers brother), 1 Ovarian
(mothers sister), 1 Throat (mothers brother), 1 Stomach (mothers father), 1 CRC
(grand fathers sister)
Yes
MSH6_2- CRC (64)
MSH6_2.1- no cancer (76)
M
M
1 CRC + Pancreatic (50 + 84 - mother),
1 Prostate (70-brother)
Yes
MSH6_3- CRC (50) F 1 CRC × 2 (64 + 71 - mother),
1 CRC & Prostate (60s - mothers 1
st cousin)
Yes
MSH6_4- CRC(72), Endometrial (74)
MSH6_4.1- CRC (37) daughter of proband
MSH6_4.2- no cancer (55)
MSH6_4.3- no cancer (18)
F
F
M
F
1 CRC (70-brother), 1 Pituitary tumour (15-brothers granddaughter),
1 Breast (60s-sister who has 1 daughter with Breast and Uterine cancer (52) and
1 daughter with Brain & Lung cancer (< 64)
No cancer in parents of proband - father d.76, mother died when proband was
6 months old
Yes
MSH6_5- CRC (58) F 1 CRC (63-mother), 3 CRC (67+78+55 - maternal half siblings), 1 Endometrial
(67-maternal half sister), 1 Liver (32-maternal half brother), 2 CRC (40+53-half
brothers children)
Yes
MSH6_6 - no information available
MSH6_6.1- no information available
MSH6_6.2- no information available
F
F
F
No pedigree available Unknown
MSH6_7- CRC (41) M 1 Hodgkins Lymphoma (13-niese), 1 Bladder (fathers sister who has 2 daughters
with Cervical cancer and a grandson with Lung cancer (19), 1 Prostate (fathers
brother), 1 Breast (40s-fathers sister), 1 CRC (70s-grandfather who has 2 brothers
with cancer of Unknown origin).
No cancer in parents of proband - age 65 + 67.
Yes
MSH6_8- CRC (?)
MSH6_8.1- Ovarian (49)
MSH6_8.2- no cancer (59)
MSH6_8.3- no cancer (29)
MSH6_8.4- Appendix (14)
M
F
F
M
F
No pedigree available Unknown
MSH6_9- Bladder (69), Endometrial (71),
Thyroid (72)
F 1 Lymphoma (77-brother), 1 CRC + Prostate (81 + 75 - brother), 1 Unknown
(42 - son)
No cancer in parents of proband - mother d.77, father d.73
Yes
MSH6_10- CRC (21), Non-Hodgkin
Lymphoma (6)
MSH6_10.1- Endometrial (68), paternal
grandmother
MSH6_10.2- Non Hodgkin Lymphoma (28),
paternal aunty
MSH6_10.3- no cancer (65)
F
F
F
F
1 CRC (70s-grandmothers uncle), 1 Breast (60-grandmothers uncle who has 1
daughter with Ovarian cancer but who is mutation negative), 1 CRC (41-
grandmothers sister’s son who is also mutation negative), 2 Breast cancer (53+? -
grandmothers sister and grandmothers aunt, both are mutation negative)
Yes
MSH6_11- CRC (40)
MSH6_11.1- no cancer (64)
MSH6_11.2- no cancer (38)
MSH6_11.3- no cancer (39)
MSH6_11.4- no cancer (31)
M
M
F
F
F
1 CRC (63-sister), 1 Prostate (56-brother), 1 Throat (maternal grandfather)
No cancer in parents - mother d.60s, dad d.70s
No
MSH6_12- no cancer (44) M 3 Endometrial (mother and maternal aunt and grandmother), 2 Unknown
(brothers - one of which is the proband somewhere else), 1 Unknown
(maternal uncle)
No/
Bethesda
MSH6_13- Endometrial (54)
MSH6_13.1- no cancer (60)
MSH6_13.2- no cancer (57)
MSH6_13.3- no cancer (37)
MSH6_13.4- no cancer (55)
MSH6_13.5- no cancer (37)
MSH6_13.6- no cancer (34)
MSH6_13.7- Endometrial (56), sister
F
F
M
F
M
F
F
F
1 CRC + Uterine (60s-mother) Yes
MSH6_14- no cancer (48) M 1 CRC + Prostate (64-father), 1 Endometrial (55-fathers sister), 1 CRC (62-paternal
grandmother)
No
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Page 5 of 10estimate is approximately half of the Australian
HNPCC/Lynch syndrome families. The identified MSH6
mutations represent 10.3% of the pathogenic mutations
identified in MMR genes in our Lynch syndrome
families. This is in accordance with the expected fre-
quencies of MSH6 mutations in already published mate-
rial on Lynch syndrome [14,20,27,28]. We report 15
novel MSH6 mutations and 1 novel PMS2 mutations in
Lynch syndrome families not listed in the Mismatch
Repair Genes Variant Database (Memorial University of
Newfoundland), the InSIGHT database as a Lynch syn-
drome mutation or the Leiden Open Variation Database
(LOVD).
Families with MSH6 mutations have been reported to
have a lower incidence of colorectal cancer (CRC) and
later age of disease onset than MLH1 and MSH2
Table 2: Mutation positive family members, type of cancer, age and gender, as well as other family cancers present in
family members with unknown mutation status (all information collected from pedigrees) and whether the family
fulfilled the Amsterdam II criteria. (Continued)
MSH6_15- CRC (54)
MSH6_15.1- no cancer (43)
MSH6_15.2- no cancer (67)
MSH6_15.3- no cancer (31)
MSH6_15.4- no cancer (70)
F
F
F
F
M
1 CRC & Ovary (47+60s - mother), 1 Endometrial/Ovarian (sister), 6 CRC
(maternal uncles), 5 CRC (maternal 1
st cousins), 1 Leukaemia (maternal 1
st
cousin), 1 Ovarian (maternal 1
st cousin)
Yes
MSH6_16- Endometrial (50), Breast (63)
MSH6_16.1- Endometrial (57), Breast (61),
sister
F
F
1 Breast (82-mother), 1 Breast (56-1
st cousin), 1 Breast (40s-mothers 1
st cousin) No
MSH6_17- no cancer (42) F 1 Endometrial (41-sister), 1 Cervix (22-sister), 1 CRC (60s-father), 1 CRC + Bladder
(mothers brother), 1 Breast (52-paternal grandmother), 1 Throat (79-paternal
grandfather, smoker)
Yes
MSH6_18- CRC (43)
MSH6_18.1- no cancer (23)
MSH6_18.2- no cancer (20)
MSH6_18.3- no cancer (55)
MSH6_18.4- Endometrial (44), sister
F
M
F
M
F
1 Lung (d.53-father), 1 Hodgkins Lymphoma (21-niese) No/
Bethesda
MSH6_19- CRC (46+67) M 1 Endometrial (49-mother), 1 Thyroid (44-daughter), 2 Unknown (mothers
sisters)
Yes
MSH6_20- CRC (48)
MSH6_20.1- no cancer 26)
MSH6_20.2- no cancer (53)
F
M
F
1 Endometrial + CRC (54+70 - mother,1 Stomach (40s-maternal grandfather) Yes
MSH6_21- CRC (31)
MSH6_21.1- no cancer (49)
MSH6_21.2- no cancer (28)
MSH6_21.3- no cancer (55)
MSH6_21.4- CRC (58), aunty
MSH6_21.5- no cancer (37)
MSH6_21.6- no cancer (60)
MSH6_21.7- no cancer (38)
MSH6_21.8- no cancer (29)
MSH6_21.9- no cancer (33)
M
F
M
F
F
F
F
M
F
F
2 CRC (39+42 - maternal uncles), 1 Lung (d.69-dad, smoker)
Mother is mutation positive but with no cancer
Yes
MSH6_22- CRC (54)
MSH6_22.1- no cancer (45)
M
F
1 CRC (48-father), 1 Ovarian (51-fathers sister), 1 CRC (34-fathers brother who
has 1 daughter with CRC (52), 1 CRC (62-fathers brother uncle), 1 Breast (67-
fathers sister)
Yes
MSH6_23- Endometrial (64), Breast (70) F No pedigree available Unknown
MSH6_24- CRC (50) F 1 Renal (father), 1 Endometrial (fathers sister), 1 Gallbladder (fathers sister), 1
Stomach (dx 56 - grandfather)
Yes
MSH6_25- CRC (63) F 1 Unknown (maternal grandfather)
No cancer in parents of proband - father d.60s, mother d.80s
No
MSH6_26- CRC (66+67)
MSH6_26.1- Bladder (52), brother
MSH6_26.2- no cancer (68)
M
M
M
F
2 CRC (59+59 - brothers), 1 Melanoma (brother)
No cancer in parents of proband - both d.80s
No
MSH6_27- CRC (38) M No family history of cancer No
MSH6_28- Endometrial (50) F 1 Uterine (50s - mother), 1 Unknown (mothers sister), 1 Uterus (52 - maternal
grandmother), 1 ALL (son), 1 Leukaemia (82 - father), 1 Prostate (paternal
grandfather)
Unknown
MSH6_29- Ovarian (38) F No pedigree available Unknown
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Page 6 of 10families [20], while others suggest same high lifetime
risk of CRC and later age of disease onset [15,29]. In
our Lynch syndrome cohort 27% had developed CRC,
which is lower than expected [30]. This could be due to
there being an over-representation of woman (68%) in
the MSH6 participants, as woman have been reported to
be at lower risk of CRC than men [30]. The median age
Table 3 Details about the extra colonic cancers observed in the MSH6 patient cohort (n = 78).
Family ID Cancer (Age of diagnosis) Family relationship Mutation in family- Nucleotide
Change
Family fulfilled Am II
criteria
MSH6_4 CRC (72)
Endometrial (74)
Proband c.2150_ 2153delTCAG Yes
MSH6_8.1 Ovarian (49) No pedigree available c.458_627del Yes
MSH6_8.4 Appendix cancer (14) No pedigree available c.458_627del Yes
MSH6_9 Bladder (69)
Endometrial (71)
Thyroid (72)
Proband c.3261delC Yes
MSH6_10 CRC (21)
Non-Hodgkin Lymphoma (6)
Proband c.1_457del Yes
MSH6_10.1 Endometrial (68) Probands paternal
grandmother
c.1_457del Yes
MSH6_10.2 Non-Hodgkin Lymphoma
(28)
Probands paternal aunty c.1_457del Yes
MSH6_13 Endometrial (54) Proband c.3202C>T Yes
MSH6_13.7 Endometrial (56) Probands sister c.3202C>T Yes
MSH6_16 Endometrial (50)
Breast (63)
Proband c.2976delA No
MSH6_16.1 Endometrial (57)
Breast (61)
Probands sister c.2976delA No
MSH6_18.4 Endometrial (44) Probands sister c.3261dupC No/Bethesda
MSH6_23 Endometrial (64)
Breast (70)
Proband c.1404_1405delTC Unknown (no pedigree)
MSH6_26.1 Bladder (52) Probands brother c.3312delT No
MSH6_28 Endometrial (50) Proband c.3556+3_3556+13delGAGTTTTTTGT Unknown
MSH6_29 Ovarian (38) Proband c.620del Unknown (no pedigree)
Figure 1 Colorectal cancer; cumulative risk for MSH6 mutation
carriers. A) sample cohort and B) sample cohort divided by gender.
Figure 2 Endometrial cancer; cumulative risk for female MSH6
mutation carriers.
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Page 7 of 10of diagnosis of CRC was 48 years in the cohort studied,
which is approximately 3-7 years younger than pre-
viously reported [20,27,31]. The median age for the rest
of the cohort was 44 years, which is an indication of the
likelihood of more people developing CRC at a later age
and thereby increasing the median age of diagnosis of
CRC. Exclusion of missense mutations in this study
could also influence the low age of CRC observed, as
cases were selected due to more severe alterations and
the chance of developing CRC earlier is therefore higher.
In this patient cohort the lifetime risk for CRC at age
70 years was ~61% independent of gender, which is
somewhat different from the lifetime risk of MSH6
mutation carriers presented in a previous study were
there was a clear difference between males and females
at age 70 years [32]. The males in both studies had simi-
lar lifetime risk, but we fail to see the lower risk in
woman. A meta-analysis of 5 different MSH6 mutation
positive Lynch syndrome cohorts displayed a much
lower lifetime risk of CRC at ~20% [33], which is an
indication that our sample cohort might be too small to
produce reliable lifetime risk figures.
The median age of endometrial cancer in this study
was 59 years, supporting the much later onset of cancer
in MSH6 mutation carriers [27]. Females in this patient
cohort had a lifetime risk of endometrial cancer of 65%
at 70 years of age, which is similar to previously
reported risk figures for MSH6 mutation carriers [32]
but again much higher than risk figures produced from
a much larger study population [33]. Endometrial cancer
w a ss e e ni n5 9 %o ft h eMSH6 families as the second
most common malignancy observed. Extra colonic can-
cers were observed with a higher frequency in the parti-
cipants who had not developed CRC compared to the
participants who had developed CRC. These observa-
tions are in accordance with the cancer frequencies seen
in the German Hereditary Nonpolyposis Colorectal Can-
cer Consortium [20]. Cancer incidence in these families
w a sa sp r e v i o u s l yr e p o r t e d[ 3 0 ]w i t hC R Cb e i n gt h e
most common, followed by endometrial cancer. Breast
and prostate cancer were observed in 23% of the MSH6
families, while ovarian cancer was observed in 17% of
the families. Both ovarian and prostate cancer were
expected to be observed in Lynch syndrome families
[34] but the inclusion of breast cancer in the cancer
spectrum in Lynch syndrome is controversial [35-39].
The high incidence of breast cancer in these families
may genuinely reflect an increased risk of breast cancer,
or it may indicate the high incidence of breast cancer in
the general population (1 in 9 woman in Australia [40]).
Previously, it has been reported that patients with
pathogenic MSH6 mutations are less frequently affected
by multiple tumours [20]. This does not seem to be the
case in our families as one or more individuals who had
been diagnosed with two primary malignancies occurred
in 14 of the 29 MSH6 families.
Currently the general consensus is that MSH6 muta-
tions in HNPCC are under-diagnosed [25,35,41]. This is
thought to be due to MSH6 not being routinely tested
in most laboratories and that the presence of MSH6
mutations is under-estimated due to a more atypical
presentation of disease, making the patients less likely to
fulfil diagnostic criteria. This is supported by a report of
an unusual high incidence of MSH6 mutations (21%) in
Amsterdam negative families [42]. In the current study,
participants were selected based on the molecular diag-
nosis of Lynch syndrome, nevertheless 24% of our
families did not fulfil the Amsterdam II criteria. There
is no routine screening for MSH6 in our laboratory and
it is only performed when there is loss of MSH6 expres-
sion in the tumour (IHC) or a family history indicating
MSH6 mutation.
PMS2 mutations lead to an attenuated phenotype with
weaker family history and an older age of onset [15].
Communicating cancer risk to PMS2 mutation carriers
and deciding which surveillance protocol is adequate for
the families is a difficult task for the genetic counsellor/
geneticist. In this study, only 6 PMS2 families were
included. While this is not enough families to be able to
predict a PMS2 phenotype, it is important that the
Table 4 PMS2 probands, type of cancer in proband and mutation information including; exon, nucleotide change,
consequence of mutation and references.
Family ID Cancer Exon Nucleotide Change Consequence of Mutation Reference
LOVD database ID
PMS2_3 CRC (55),
Renal (50)
1 8 c.1A>G
+c.834_842del
Alternative DNA transcript Deletion DB-ID: PMS2_00130
PMS2_1
PMS2_2
PMS2_5
CRC (41)
No cancer (67)
CRC (47)
7 c.736_741del6ins11 Truncating DB-ID: PMS2_00187
PMS2_4 CRC (38) 7 c.746_753del Truncating Not previously reported
PMS2_6 CRC (60) 9 c.904_1144del Exon deletion DB-ID: PMS2_00195
4 different PMS2 mutations have been detected in our patient Cohort. Not previously reported = not reported in the Leiden Open Variation Database (LOVD), the
Mismatch Repair Genes Variant Database (Memorial University of Newfoundland) or the InSIGHT database as a HNPCC/Lynch syndrome mutation. DB-ID =
Database identification number from LOVD.
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type can be made in the future.
Lynch syndrome is a complex disease with variation in
disease expression influenced by both genetic and envir-
onmental factors, as evidenced by differences in geno-
type-phenotype within and between families with the
same mutations and by ethnicity and mutated MMR
gene [43-45]. To date, no worldwide genotype-pheno-
type correlation has been detected. Our data provides
additional information to add to the genotype-pheno-
type spectrum for both MSH6 and PMS2 mutations. As
approximately half of the clinically diagnosed HNPCC
population can be classified as having Lynch syndrome
(germline mutation in MMR genes), there are most
likely other genomic regions that are also responsible
for the disease. Future next-generation sequencing are
likely to provide us with some answers by locating new
genomic regions of interest, as shown by identification
of the EPCAM deletion [46], but until the methodology
is widely available the candidate gene approach in indi-
vidual Lynch syndrome cohorts will help us in under-
standing the genotype-phenotype mystery.
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